Certificate in terms of Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals Ltd has submitted a compliance certificate to BSE under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2025. The certificate, issued by KFin Technologies Limited (the company's Registrar and Share Transfer Agent), confirms that share certificates received for dematerialization during the quarter were properly processed — approved/rejected within 15 days, listed on stock exchanges, mutilated and cancelled after verification, and the depository's name was substituted in the register of members. Separate confirmations were sent to both NSDL and CDSL. The filing was signed by Bharat Sharma, Managing Director, on April 8, 2025.
This is a routine quarterly compliance filing with no material impact on the company's operations, financials, or share price. It simply confirms the proper handling of share dematerialization requests for the January–March 2025 quarter.